Lexeo Therapeutics (LXEO) Income from Continuing Operations (2022 - 2026)
Lexeo Therapeutics recorded quarterly Income from Continuing Operations of 20196000.0 in Q1 2026, up 3.47% quarter-over-quarter from 20923000.0 in Q4 2025, and up 38.16% year-over-year from 14618329.99 in Q1 2025.
Lexeo Therapeutics' Income from Continuing Operations history runs 5 years deep, the most recent figure standing at 20196000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 38.16% year-over-year to 20196000.0; the TTM figure through Mar 2026 stood at 87505000.0 (up 19.95% YoY), while the FY2025 annual figure was 103222000.0, down 4.97% from the prior year.
- Income from Continuing Operations came in at 20196000.0 for Q1 2026 at Lexeo Therapeutics, up from 20923000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 13441000.0 in Q2 2023 to a low of 32656000.0 in Q1 2025.
- A 5-year average of 21101266.67 and a median of 20283000.0 in 2025 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations plunged 82.73% in 2024 and surged 38.16% in 2026, its largest moves.
- Lexeo Therapeutics' Income from Continuing Operations stood at 14577000.0 in 2022, then increased by 2.68% to 14187000.0 in 2023, then plunged by 82.73% to 25924000.0 in 2024, then rose by 19.29% to 20923000.0 in 2025, then increased by 3.47% to 20196000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 20196000.0, 20923000.0, and 20283000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Lexeo Therapeutics | 392.12 Mn | 199.07 Mn | - | -20.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.20 Mn |
| Dec 31, 2025 | -20.92 Mn |
| Sep 30, 2025 | -20.28 Mn |
| Jun 30, 2025 | -26.10 Mn |
| Mar 31, 2025 | -32.66 Mn |
| Dec 31, 2024 | -25.92 Mn |
| Sep 30, 2024 | -29.49 Mn |
| Jun 30, 2024 | -21.24 Mn |
| Mar 31, 2024 | -21.68 Mn |
| Dec 31, 2023 | -14.19 Mn |
| Sep 30, 2023 | -20.11 Mn |
| Jun 30, 2023 | -13.44 Mn |
| Mar 31, 2023 | -18.66 Mn |
| Dec 31, 2022 | -14.58 Mn |
| Sep 30, 2022 | -17.06 Mn |